AstraZeneca thyroid cancer drug gets EU approval
UK pharmaceutical manufacturer AstraZeneca has been given a boost by European drug regulators who have approved its vandetanib drug as a potential treatment for thyroid cancer.
Vandetanib, also sold and marketed under the brand name Caprelsa, has a turbulent past few years and AstraZeneca will no doubt breathe a sigh of relief at its approval.
The drug will treat medullary thyroid cancer (MTC) tumours which are not suitable for surgical removal and have spread to other areas of the body.
To read the latest edition of Healthcare Global, click here
- Antibiotic resistant superbugs spread across Europe
- Fertility treatments increase by almost six percent
- NHS redesigns A&E departments to stop patient abuse
Approval of the drug came after the regulators reviewed the Phase III clinical trial data, which revealed using Caprelsa reduces the risk of the disease progressing by 54 percent by preventing blood from flowing to tumours and inhibiting their growth.
At the moment there are no approved treatments for MTC in Europe.
When Caprelsa first emerged on the pharmaceutical scene it was tipped to be a blockbuster drug and was estimated to be worth $1billion to the company.
However, the drug hit a stumbling block when, in clinical trials, it was unable to extend the lives of cancer sufferers.
Pharmaceutical industry experts are now predicting the drug will not prove to be a blockbuster for AstraZenca, as it is targeted at a niche market as MTC affects only four percent of thyroid cancer sufferers.
Forecasts published on Thomson Reuters Pharma have estimated in five years time, by 2016, sales of Caprelsa will reach $112million, a far cry from its original £1billion estimations.
Our magazine is now available on the iPad. Click here to download it.
LG launches purpose-built smart TV for hospitals
LG Business Solutions USA has announced two new hospital TVs that are designed to improve patient management and engagement while adhering to critical safety standards for healthcare facilities.
One of the TVs is LG's biggest ever screen for a hospital - the 65-inch 4K Ultra HD model. It has LG’s NanoCell display technology, enabling it to display vivid pictures, and provides built-in support for hospital pillow speakers and embedded broadband LAN capability, so hospitals can deliver video on demand without requiring a separate set-top box in the patient room.
It also includes configuration software with an intuitive interface for setting up the TV to work in a hospital setting, plus a software-enabled access point feature that turns the TV into a Wi-Fi hotspot.
The second TV screen is the 15-inch Personal Healthcare Smart Touch TV with a multi-touch screen. It is designed to be installed on an adjustable arm for use in shared spaces or smaller patient rooms and will support LG's new, modular LG AM-AC21EA video camera, and HD video communication.
Both include support for video conferencing, and are UL Certified for use in healthcare facilities, a global safety standard. They also feature LG’s integrated Pro:Centric hospital management solutions, allowing hospitals and LG’s patient engagement development partners to personalise a patient's room, providing entertainment, hospital information, services, patient education, and more.
Additionally its communication platform makes it possible to conduct video calls between patients and clinicians or family.
“Our newest LG hospital TVs reflect ongoing feedback from the industry and include capabilities integrated to meet the unique needs of a critical market” said Tom Mottlau, Director of Healthcare Solutions, LG Electronics USA.
“Our healthcare patient engagement development partners requested an upgradable version of webOS for our Pro:Centric smart TV platform so they could more easily introduce new features for their hospital customers. For the latest versions of webOS, LG worked closely with our partners to make their request a reality and to deliver a hospital TV platform that can evolve over time.”